Cusack Thomas 4

What Happened Thomas Cusack, a director of Heron Therapeutics, was granted 53,960 restricted stock units (RSUs) on January 30, 2026. The reported acquisition price is $0.00 per unit (award), so the transaction shows $0 cash paid; each RSU is a contingent right to one share of common stock and will convert to shares upon vesting. This is an equity compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-30; Transaction type: Award/Grant (code A)
• Quantity: 53,960 RSUs; Reported acquisition price: $0.00 (award)
• Vesting: RSUs vest in full on January 30, 2027 (see footnote)
• Shares owned after transaction: Not disclosed in the provided filing excerpt
• Filing date: 2026-02-03 — appears timely (filed within the SEC’s two-business-day window)
• Footnote: Each RSU represents a contingent right to one share; subject to vesting conditions and possible forfeiture/tax withholding

Context RSU grants to directors are common as compensation and do not represent a market purchase or sale—therefore they should not be read as a direct bullish or bearish signal. These RSUs will only become actual shares (and potentially taxable) if and when they vest on January 30, 2027.